FILE PHOTO: The exterior of the European Medicines Agency is seen in Amsterdam, Netherlands, December 18, 2020. REUTERS/Piroschka van de Wouw/File Photo
(Reuters) – The European medicines regulator said on Monday it would hold a meeting this week on the information gathered into whether the AstraZeneca COVID-19 vaccine contributed to thromboembolic events in those inoculated.
While its investigation is ongoing, the European Medicines Agency remains of the view that the benefits of the AstraZeneca vaccine in preventing COVID-19 outweigh the risks of side effects. (bit.ly/3trmufB)
Reporting by Yadarisa Shabong in Bengaluru; Editing by Shounak Dasgupta
Our Standards: The Thomson Reuters Trust Principles.
The bank’s new Innovation Banking and Fund Banking brands signal its intended positioning, not proof…
U.S. Bank’s enhanced automotive cards emphasize dealership and loan redemptions, while their value to drivers…
A partnership with Youth Sport Trust connects athletics with financial education and mental-health support, but…
The global 4K satellite broadcasting market was valued at USD 33.9 billion in 2024 and…
New multi-million-pound FIA Remote Operations Centre underlines FIA commitment to delivering highest standards of safety,…
A review published through the Harvard Law School Forum on Corporate Governance describes fewer campaigns,…